BMO Capital reiterated an Outperform rating and $23.00 price target on BioXcel Therapeutics (NASDAQ: BTAI) following BXCL501 phase 1 data ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE